GEMBLOUX, Belgium, May 16, 2024
/PRNewswire/ -- Full-Life Technologies (Full-Life), a fully
integrated global radiotherapeutics company, today
announced the appointment of Mark S.
de Jong, PhD, to the newly created position of Chief
Technical Officer (CTO). Dr. de Jong, joins Full-Life with 43 years
leadership experience and expertise in accelerator physics, and
isotope production, including commercial-scale radioisotope
production using linear accelerators. He joined Full-Life from
Canadian Isotope Innovations Corp., where he served as Chief
Technology Officer.
At Canadian Isotope Innovations Corp., he spearheaded the
development and operation of the MIP (Medical Isotope Production)
facility with a 35 MeV electron linear accelerator dedicated to
medical isotope production. His responsibilities included leading
the development of new radioisotopes for medical applications
utilizing electron accelerators, as well as leading the development
of electron accelerators and target technology for medical isotope
production.
Previously, Dr. de Jong held the position of Chief Medical
Isotope Officer at Canadian Light Source Inc. (CLS). During his
tenure there, he led the development, operation, and
commercialization of the MIP facility using a 35 MeV electron
linear accelerator dedicated to producing Molybdenum-99
(99Mo) for medical applications. His leadership has been
instrumental in numerous successful groundbreaking projects,
including the design and commissioning of a 2.9 GeV electron
synchrotron for CLS, and pioneering a photo-neutron method for
producing 99Mo. He has also developed critical software
tools for nuclear safety systems for power plants, ensuring their
safe operation.
Dr. de Jong's distinguished career is marked by his exemplary
leadership and active participation in numerous prestigious
national and international committees. Notably, he served as the
Chief Scientific Investigator for the International Atomic Energy
Agency's Coordinated Research Project on new methods for producing
Technetium-99m (Tc-99m), a critical medical isotope. He has also
held leadership positions on international advisory committees,
including the Taiwan Photon Source and the Shanghai Synchrotron
Radiation Facility.
Dr. de Jong's dedication to scientific advancement is further
evidenced by his contributions to international organizations like
the International Electrotechnical Commission and the OECD Nuclear
Energy Agency. Dr. de Jong's contributions to the field have been
recognized with renowned awards, including the AECL Distinguished
Merit Award and the University of
Manitoba Honoured Alumni Award. He holds a PhD in Physics
from the University of Manitoba.
"Dr. de Jong brings a distinguished background in particle
accelerator technology, especially within the pharmaceutical
sector. His role will be impactful in leading our efforts to
implement a state-of-the-art particle accelerator for radioisotope
production," said Philippe van Put, General Manager of
Full-Life Technology Europe. "With his extensive experience in
medical isotope production and a proven track record in developing
and managing electron accelerator facilities, Dr. de Jong is
well-equipped to drive our projects to the next stage of
development. His leadership skills, technical prowess, and
long-term strategic management of accelerator facilities have
earned him international recognition and a place on prestigious
committees and projects. We are excited about the fresh
perspectives and innovative approaches Dr. de Jong will bring to
our team."
About Full-Life Technologies
Full-Life Technologies Limited ("Full-Life") is a fully
integrated global radiotherapeutics company with operations in
Belgium, Germany, and China. We aim to own the entire value chain
for radiopharmaceutical research & development, production
& commercialization in order to deliver clinical impact for
patients. The Company plans to attack core issues affecting
radiopharmaceuticals today through innovative research that targets
the treatments of tomorrow. We are comprised of a team of
fast-moving entrepreneurs and scientists with a demonstrated track
record in the life sciences, as well as radioisotope research and
clinical development.
View original
content:https://www.prnewswire.com/news-releases/full-life-technologies-announces-appointment-of-mark-s-de-jong-phd-as-chief-technical-officer-302144370.html
SOURCE Full-Life Technologies Limited